Breaking News


BioClinica Sued by Shareholder Over Sale to JLL Partners

BioClinica Inc. (BIOC), which provides clinical trial management services, was sued by an investor who claims the stock is undervalued in a $123 million buyout offer from New York private-equity firm JLL Partners Inc.

Because of the company’s future prospects, directors of Newtown, Pennsylvania-based BioClinica could have negotiated a higher price than the agreed-upon $7.25 a share, said James Gerson in the Delaware Chancery Court complaint made public today in Wilmington.

“Despite the persistent economic downturn throughout the United States, the company has seen a significant operating improvement in the last 12 months,” lawyers for Gerson said in the filing. They ask a judge to halt the transaction under its present terms and to award damages.

Mark Weinstein, BioClinica’s chief executive officer, didn’t immediately respond to a request seeking comment on the lawsuit.

BioClinica, which reported $83.9 million in 2011 sales, fell 3 cents to $7.23 at 12:34 p.m. in New York.

The case is Gerson v. BioClinica, CA8272, Delaware Chancery Court (Wilmington).

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at

To contact the editor responsible for this story: Michael Hytha at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.